Pharmaceuticals

Pulmonary Drugs Market Forecast 2026–2035: How to Leverage Market Growth

February 18, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pulmonary drugs market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Pulmonary Drugs Market between 2026 and 2030?

The pulmonary drugs market has experienced substantial growth in recent years. It is expected to expand from $56.98 billion in 2025 to $60.07 billion in 2026, at a compound annual growth rate (CAGR) of 5.4%. The growth witnessed in the past can be attributed to an increase in asthma prevalence, rising COPD incidence, the proliferation of urban air pollution, the expansion of inhalation drug delivery, and improved diagnosis of respiratory diseases.

The pulmonary drugs market size is poised for robust expansion in the coming years. It is projected to reach $74.14 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period can be attributed to an increasing aging population, the broadening availability of biologic pulmonary drugs, the integration of precision respiratory medicine, a rise in smoking-related ailments, and improved access to inhaled therapies. Significant trends expected in this period include the growing acceptance of targeted respiratory therapies, the proliferation of combination inhalation treatments, an intensified focus on long-term disease management, the expansion of biologic-based pulmonary drugs, and a shift towards personalized respiratory care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Which Drivers Are Expected To Impact The Pulmonary Drugs Market During The Forecast Period?

The escalating occurrence of respiratory diseases is projected to boost the pulmonary drugs market’s growth in the future. Respiratory disorders are defined as medical conditions that impact the lungs and airways, hindering normal breathing and oxygen exchange. The rise in these disorders is largely due to the increasing prevalence of smoking, which leads to lung damage and various chronic diseases. Pulmonary drugs are essential for managing respiratory disorders by improving lung function, decreasing inflammation, and relieving airway obstruction, thereby facilitating better breathing. For instance, in May 2025, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, with higher rates in women (4.1%) than men (3.4%). Furthermore, COPD prevalence rose sharply with age, from 0.4% in adults 18–24 to 10.5% in those 75 and older. Therefore, the growing incidence of respiratory illnesses is a key driver for the expansion of the pulmonary drugs market.

How Is The Pulmonary Drugs Market Divided Into Segments?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

How Are New Market Trends Shaping The Landscape Of The Pulmonary Drugs Market?

Major companies in the pulmonary drugs market are focusing on therapeutic innovations, such as the inhaled delivery of dual PDE3 and PDE4 inhibition, to combine bronchodilator and non-steroidal anti-inflammatory effects within a single molecule for the continuous treatment of chronic obstructive pulmonary disease (COPD). This dual PDE3 and PDE4 inhibition allows for simultaneous airway relaxation and reduction of lung inflammation, addressing persistent COPD symptoms more effectively than traditional therapies and simplifying administration without requiring complex inhalation techniques. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, received U.S. FDA approval for Ohtuvayre (ensifentrine), which is the first inhaled therapy with this dual-mechanism profile in more than 20 years. Delivered via standard jet nebulizer, Ohtuvayre provides bronchodilator and anti-inflammatory benefits in a single dose, demonstrating clinical efficacy both as monotherapy and in combination with other maintenance treatments in the Phase 3 ENHANCE trials, and is expected to be available through specialty pharmacies in the U.S. by the third quarter of 2024.

Which Major Firms Are Strengthening Their Position In The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pulmonary Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795